Antiviral therapy of chronic hepatitis BMust be stopped according to guideline standards. For HBeAg positive, then to consolidate the treatm
Antiviral therapy of chronic hepatitis B
Must be stopped according to guideline standards. For HBeAg positive, then to consolidate the treatment of a HBeAg seroconversion after the initial treatment of patients; for HBeAg negative, the total course of at least 2 and a half years; 1.5 years of treatment to consolidate treatment to achieve sustained virological control after prolonged treatment to reduce the recurrence when necessary.
Regular follow-up after treatment, there are signs of recurrence and evidence of disease progression, the beginning of a new antiviral treatment.
In particular, it has been demonstrated that only HBsAg seroconversion in patients with HBeAg negative hepatitis B can effectively reduce the rate of relapse after discontinuation of the drug.